Cargando...
Extended interval dosing of natalizumab: a two-center, 7-year experience
BACKGROUND: The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple sclerosis (MS), has been tempered by the risks of progressive multifocal leukoencephalopathy associated with its use, and strategies to minimize those risks are of great interest. Extended interval do...
Gardado en:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4206618/ https://ncbi.nlm.nih.gov/pubmed/25342976 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285614540224 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|